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Abstract
Background: Morbidity and mortality patterns among pregnant women and their infants (before
antiretroviral therapy was widely available) determines HIV-1 diagnostic, monitoring, and care
interventions.
Methods: Data from mothers and their infants enrolled in a trial of antibiotics to reduce mother-to-
child-transmission of HIV-1 at 4 sub-Saharan African sites were analyzed. Women were enrolled
during pregnancy and follow-up continued until the infants reached 12 months of age. We describe
maternal and infant morbidity and mortality in a cohort of HIV-1-infected and HIV-1-uninfected
mothers. Maternal and infant factors associated with mortality risk in the infants were assessed using
Cox proportional hazard modeling.
Results: Among 2292 HIV-1-infected mothers, 166 (7.2%) had a serious adverse event (SAE) and
42 (1.8%) died, whereas no deaths occurred among the 331 HIV-1 uninfected mothers. Four hundred
twenty-four (17.8%) of 2383 infants had an SAE and 349 (16.4%) died before the end of follow-up.
Infants with early HIV-1 infection (birth to 4 – 6 weeks) had the highest mortality. Among infants
born to HIV-1-infected women, maternal morbidity and mortality (P = 0.0001), baseline CD4 count
(P = 0.0002), and baseline plasma HIV-1 RNA concentration (P < 0.0001) were significant predictors
of infant mortality in multivariate analyses.
Conclusions: The high mortality among infants with early HIV-1 infection supports access to
HIV-1 diagnostics and appropriate early treatment for all infants of HIV-1-infected mothers. The
significant association between stage of maternal HIV-1 infection and infant mortality supports
routine CD4 counts at the time of prenatal HIV-1 testing.
Keywords
HIV-1 infection; infant mortality; maternal morbidity and mortality; sub-Saharan Africa; pregnant
women
The HIV-1 epidemic in sub-Saharan Africa continues to expand and affect women and children
disproportionately.1 In recent years, with support from a variety of donor organizations,
including the Global Fund on AIDS, Tuberculosis and Malaria, and the President's Emergency
Plan For AIDS Relief (PEPFAR), significant progress has been made in increasing the
availability of antiretroviral therapy (ART) and the number of prevention of mother-to-child
transmission (PMTCT) programs.2,3 However, for a variety of logistical, financial, and socio/
cultural reasons, these programs are not covering all in need. In Malawi, for example, there
are now more than 100,000 persons who have initiated ART since December 2003.4 However,
it is predicted that 1 million are infected with HIV, 200,000 require ART, and each year another
81,000 become infected and will need ART in the coming years.4 Many HIV-1-infected adults
and children in this region of the world still go undiagnosed, or even if diagnosed, are often
lost to the health care system and present for care too late even for ART to help.5,6
From mid-2001 to early-2003, a multisite clinical trial (HIVNET 024) took place in Malawi,
Tanzania, and Zambia to evaluate the efficacy of antibiotics for prevention of chorioamnionitis-
related mother-to-child transmission (MTCT) of HIV-1.7,8 HIV-1-infected and uninfected
pregnant women were enrolled in their second trimester and followed periodically, along with
their infants, for 12 months after delivery. The study began before ART was readily available
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in these countries. The routine provision of nevirapine prophylaxis for PMTCT during the
conduct of this trial was among the first utilizations of the HIVNET 012 findings in the region.
8
As part of the safety objectives of this study, and in accordance with Good Clinical Practice
(GCP), all serious adverse events (SAEs), including all maternal and infant deaths were
documented and reported. Thus, this study is one of the last controlled trials in sub-Sahara
Africa that documents the natural history of HIV-1 disease for pregnant women and their
newborns.
Many gaps remain in HIV-1 care programs in sub-Saharan Africa, particularly in the areas of
early diagnosis, ART access, and CD4 monitoring. We undertook this tertiary analysis from
this large clinical trial to determine the morbidity and mortality patterns among African women
and infants from the second trimester of pregnancy among women and among the mother infant
pairs from delivery to 12 months postpartum. Knowledge of these factors might inform ART
treatment and care programs, particularly the time frame when HIV-1-infected pregnant




We conducted an observational cohort analysis from HIVNET 024, a randomized, double
blinded, placebo-controlled, phase III trial of antibiotics intended to reduce MTCT of HIV-1
and preterm birth.8 Enrollment began in July 2001 and the last delivery occurred in July 2003.
Recruitment into the study was stopped by the Data and Safety Monitoring Board (DSMB) in
March 2003 when it became apparent that the intervention was unlikely to reduce MTCT of
HIV-1, the primary objective of the study. No further antibiotics were dispensed after March
2003. This trial was conducted at 4 sub-Saharan African sites in 3 countries: Blantyre and
Lilongwe, Malawi; Dar es Salaam, Tanzania; and Lusaka, Zambia. The Institutional Review
Boards (IRBs) of each African and collaborating U.S. institution approved the protocol.
Within these sites, participants were recruited from multiple hospitals and antenatal clinics.
All pregnant women attending their first antenatal visit were informed of the study. After
administration of HIV-1 voluntary counseling and testing and confirmation of HIV-1 status,
HIV-1-infected women were enrolled in the trial after an informed consent process and
randomly assigned to receive either antibiotics or placebo at 20–24 weeks gestation. To reduce
the stigma for the women with HIV-1, in 3 of the 4 sites, for every 5 women with HIV-1, 1
HIV-1-uninfected woman was enrolled. Dar es Salaam recruited only HIV-1-infected women.
After enrollment, follow-up visits were conducted at 26, 30, and 36 weeks, and at labor/
delivery. During these visits, women were interviewed using structured questionnaires, a
physical examination was performed, and laboratory samples were obtained. Infant study visits
were conducted at birth (within the first 48 hours), at 4–6 weeks (with an allowable window
up to 8 weeks), and at 3, 6, 9, and 12 months.
In addition to routine antenatal care, women were screened for syphilis and other genital tract
infections during pregnancy and treated at no cost. All HIV-1-infected women participating in
this trial and their infants were offered, and most received nevirapine according to the HIVNET
012 regimen for prevention of MTCT of HIV-1.9 Cotrimoxazole prophylaxis was given to
HIV-exposed infants. HIV-1-infected women and children were referred for HIV-1 care at
each of the participating study sites. However, antiretroviral drugs were not available at any
of the study sites at that time.
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HIV-1 diagnostic testing of the women was performed according to site-specific procedures
that included either a rapid test or ELISA/Western blot tests. All initially positive HIV-1 test
results were confirmed on site. Maternal blood was collected to perform a complete blood
count, CD4 cell count, and plasma viral load. Infant HIV-1 infection was determined by RNA
PCR at birth, 4–6 weeks, and quarterly through 9 months and by ELISA/WB at 12 months.8
For confirmation of the infant's HIV-1 infection a second sample from a subsequent visit was
tested whenever possible. Infants who were lost to follow-up or died before testing were
classified as having an unknown HIV-1 infection status. Maternal plasma viral load was
measured as previously described.8
Adverse Event Reporting
Adverse events (AEs) were graded according to the NIAID DAIDS Toxicity Table
(http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/Safety/
DAIDSAEGradingTable.pdf) and adapted to local population normal values including all
laboratory values. For example, the definition of all grades of anemia was lower at each study
site compared with the DAIDS toxicity tables. The 5 toxicity grades that were assigned to an
AE were defined as follows: grade 1 (mild), grade 2 (moderate), grade 3 (severe), grade 4 (life-
threatening), and grade 5 (death). The relationship between an AE and the investigational
product (nevirapine) was determined by the site investigator or subinvestigator. All AEs,
regardless of their relationship to nevirapine, were entered into the study database if they
occurred within 2 weeks of exposure to the study antibiotics or within 8 weeks of exposure to
nevirapine. The following SAEs were reported throughout follow-up regardless of whether
they took place within 8 weeks of exposure to nevirapine: death, congenital anomaly or birth
defect, stillbirth, or spontaneous abortion.
Statistical Analysis
For this analysis, we define maternal SAEs as those AEs that occurred after enrollment and up
to 12 months postdelivery that resulted in death, stillbirth, new or prolonged hospitalization,
and AEs considered to be life-threatening (grade 4 events). Infant SAEs were defined as
congenital anomalies, AEs that resulted in death, new or prolonged hospitalization, or were
life-threatening (grade 4) that occurred after birth and up to 12 months of age. For HIV-1-
infected infants, timing of HIV-1 infection was determined by the specimen collection date of
the first positive HIV-1 test, and categorized as early infection (positive results by 8 weeks of
age), late infection (negative results throughout 8 weeks, followed by a positive result after
week 8), and infection of unknown timing (missing test result at 4–8 weeks, and positive result
after week 8). Two infants with indeterminate HIV-1 status were excluded from any analysis
assessing the impact of infant HIV-1 status on SAEs or mortality. Infants with only negative
test result(s) during follow-up (birth to 12 months of age) were categorized as “uninfected,”
although we recognize that some of the infants in this category could have been infected either
after censoring or in between the last negative test and death.
Frequency tables were used to describe the distribution of SAEs and mortality by etiology. The
proportions of participants experiencing SAEs or death were compared between study sites
using either Pearson χ2 test or Fisher exact test.
Kaplan-Meier curves were used to describe infant survival time distribution by strata. Mortality
rates and the corresponding 95% confidence intervals were calculated based on the person-
year analysis assuming an underlying Poisson distribution. Cox proportional hazard modeling
was performed to identify maternal and infant factors associated with risk of death in the
infants. Variables included in the multivariate models were based on biologic or
epidemiological importance or statistical significance (P ≤ 0.05) in univariate analysis.
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All statistical calculation and analyses were performed using SAS version 9.1.3 on SunOS 5.9
platform.
RESULTS
Size and Characteristics of the Study Population
We enrolled 2659 women in their second trimester of pregnancy at the 4 sites between July
30, 2001 and March 5, 2003, including 2292 (86.2%) HIV-1-infected women and 367 (13.8%)
HIV-1-uninfected women. One hundred fifty-eight HIV-1-infected women (6.9%) and 28
HIV-uninfected women (7.6%) were lost to follow-up before delivery. HIV-1-infected women
delivered 2078 live-born infants; of these, 2026 singleton and 26 first-born twins were included
in this analysis. Three hundred thirty-one HIV-1-uninfected women delivered a live-born infant
of whom 327 singleton and 4 first-born twins were included in this analysis. Among these 2383
infants, 1562 (66%) were followed until the end of the study (51 at 6 months, 212 at 9 months,
and 1299 at 12 months of age). Three hundred forty-nine (15%) infants died before 12 months
of age. Four hundred seventy-four (20%) infants terminated early from study participation
because of relocation of the family (64%), parents refusing further participation (32%), or
maternal death (1.8%).
The median age among HIV-1-infected women was 25 years and the median age among HIV-1-
uninfected women was 22 years. The median number of years of education among both HIV-1-
infected and uninfected women was 7 years. There were no differences in the rate of maternal
SAE and mortality, infant SAE and mortality, or infant HIV-1 infection among the
randomization arms.8
SAEs and Mortality Among Mothers
Among 2292 HIV-1-infected mothers, 166 (7.2%) had an SAE and 42 (1.8%) died (Table 1).
Thirty-five (83%) deaths occurred after delivery and 7 (17%) occurred before delivery. No
deaths occurred during labor and delivery. The incidence of maternal SAEs and mortality did
not differ among the 4 sites. Of uninfected mothers, 12 (3.3%) experienced an SAE but none
died (Table 1). Ten SAEs occurred during labor/delivery and 2 occurred before delivery.
Stillbirth was the most common SAE among all mothers, comprising 37% (77) of AEs in
HIV-1-infected mothers and 67%8 of AEs in uninfected mothers. There was no difference in
stillbirth based on baseline maternal syphilis status; stillbirth occurred in 3.7% of women
positive for syphilis at baseline and in 3.2% of women negative for syphilis at baseline (P =
0.7). Other frequently reported SAEs among HIV-1-infected women were anemia (n = 23,
11%), malaria (n = 17, 8%), and tuberculosis (n = 14, 7%).
Fifty-seven etiologies were attributed to the 42 deaths among HIV-1-infected mothers. Anemia
(n = 11, 19%), sepsis (n = 8, 14%), tuberculosis (n = 6, 10%), and malaria (n = 6, 10%) were
the most common causes of death, together accounting for about 53% of deaths. Other
significant causes of death included meningitis (n = 4, 7%), pneumonia (n = 5, 8%), AIDS-
related complex (n = 3, 5%), and Kaposi Sarcoma (n = 3, 5%). The cause of death was unknown
for 2 women. Among the 8 sepsis deaths, 5 occurred within 6 weeks after delivery and were
possibly related to labor and delivery complications.
HIV-1-infected women with enrollment CD4 lymphocyte counts <200 cells/mm3 had a higher
mortality rate (6.1/100 person years, 95% CI: 3.9 –9.1) than women with CD4 counts of 200–
500 cells/mm3 (1.1/100 person years, 95% CI: 0.5–1.9) or ≥500 cells/mm3 (0.4/100 person
years, 95% CI: 0.1–1.5). Mortality was greater among women with plasma HIV-1 RNA
concentrations ≥50,000 copies/mL (5.1/100 person years, 95% CI: 3.5–7.2) than among
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women with plasma HIV-1 RNA concentrations <50,000 copies/mL (0.6/100 person years,
95% CI: 0.2–1.1).
SAEs and Mortality Among Infants
The infant mortality rates did not differ among the sites (P = 0.58). Overall, 424 infants had
an SAE (17.8%) and there were 349 deaths (14.6%) among 2383 live-born infants followed
for a median of 365 days. The proportion of infants with SAEs varied by site among infants
born to HIV-1-infected women (Table 1).
Pneumonia was the most frequently reported SAE and cause of death among all infants,
accounting for 22.5% of all SAEs and 30.4% of all deaths (Table 2). Other SAEs frequently
experienced by all infants were sepsis, diarrhea, and malaria which together totaled 21.7% of
all SAEs. Forty-nine (9.2%) instances of sepsis were reported 14 (5.9%) times among HIV-1-
infected infants and 31 (12.8%) times among HIV-1-uninfected infants. Diarrhea and
gastroenteritis were reported 40 (7.5%) times for all infants and 25 times (10.6%) for HIV-1-
infected infants and 15 times (6.2%) among HIV-1-uninfected infants. Malaria was the etiology
of 26 (4.9%) SAEs (10 [4.2%] SAEs among HIV-1-infected infants and 16 (6.6%) SAEs among
HIV-1-uninfected infants).
To assess how the timing of acquisition of HIV-1 infection affected infant mortality, deaths
occurring before and after week 8 (day 56) were examined separately. By week 8, 104 (5.1%)
infants born to HIV-1-infected women died compared with 10 (3%) infants born to HIV-1-
uninfected women. Among the 104 infants, 48 had no HIV-1 test before death, 9 had a positive
HIV-1 diagnostic test result, and 47 had a negative test result but no positive test result before
death. For infants with follow-up beyond 8 weeks of age, those who were infected early (at
birth or by 4–6 weeks) experienced significantly greater mortality (Fig. 1, Table 3).
Infant Mortality Related to Maternal HIV-1 Infection Status
Infants born to HIV-1-infected mothers were more likely to die during the follow-up period
than infants born to HIV-1-uninfected mothers (hazard ratio and 95% CI, 3.9 [2.3, 6.9]).
Additionally, infant mortality was higher among infants born to both HIV-1-infected and
HIV-1-uninfected mothers who experienced an SAE (including death) than among infants
whose mothers did not experience an SAE (hazard ratio and 95% CI, 5.8 [3.5, 9.4]) (Table 4).
Among infants born to HIV-1-infected women, maternal CD4 counts at enrollment were
inversely related to infant mortality; compared with infants born to mothers with CD4 count
≥500 at enrollment, the mortality was higher among infants born to mothers with CD4 count
<200 (hazard ratio and 95% CI, 3.1 [2.2, 4.2]) and infants born to mothers with CD4 count
between 200 and 500 (hazard ratio and 95% CI, 1.6 [1.2, 2.2]). Infant mortality was higher
among those born to mothers with higher RNA viral loads (hazard ratio and 95% CI for 1 unit
increase in log10 viral load, 2.3 [2.0, 2.8]) (Table 4).
In multivariate analyses, maternal HIV-1 infection, morbidity, and mortality were significant
predictors of infant mortality among all infants (Table 4). Among infants born to HIV-1-
infected mothers, maternal morbidity, mortality, baseline CD4 count, and baseline plasma
HIV-1 RNA concentration were all significant predictors of infant mortality (Table 4).
DISCUSSION
This multisite study was conducted in Africa at a time when there were few opportunities to
access ART or adequate care for opportunistic infections. Since late 2003, national programs
have scaled up and now provide ART to large numbers of infected individuals, dramatically
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improving the survival and quality of life for those involved. These data describe the natural
history of HIV disease in antenatal women and their infants before ART availability.
In this study, mortality among mothers and infants did not differ among sites.
Two percent of the HIV-infected women died during the follow-up period that began in their
second trimester of pregnancy and continued for 12 months after delivery. There were no deaths
among the 367 HIV-negative women and only 3% of these women had a SAE, illustrating the
differences between HIV uninfected and infected women. Each of the countries where the
study was conducted have some of the highest maternal mortality ratios in the world: Malawi
984 per 100,000 live births,10 Tanzania 578 per 100,000 live births,11 Zambia 729 per 100,000
live births.12 However, although the majority of SAEs occurred during labor and delivery for
all women, 90% of deaths occurred postnatally and no deaths occurred during labor and
delivery. These findings suggest that the high maternal mortality reported in these countries
may be more directly influenced by the underlying health status, such as HIV-status and
anemia.
The primary cause of death among these women was anemia. The prevalence of anemia is high
among women in sub-Saharan Africa. National population-based surveys estimate 44% of
women in Malawi and 48% of women in Tanzania are anemic.10,11 Anemia is a leading
contributor to maternal morbidity and mortality in developing countries13 and is caused
primarily by malaria, intestinal parasites and HIV itself. Our results support the role of reducing
anemia in women to reduce maternal mortality, especially among HIV-infected women.
Infant mortality, with or without HIV infection, is high in these countries. In contrast to the
maternal cohort in which only 25% of SAEs resulted in death, the majority of SAEs (82%)
among the infants resulted in death. Mortality was high in this cohort of infants where 86% of
the mothers were HIV-infected and 20% of the infants were HIV infected by the end of the 12
month follow-up period. Almost 15% of the infants in the cohort died during this follow-up
period (146 per 1000 live births), higher than the all infant mortality in Tanzania (68 per 1000
live births),11 Zambia (95 per 1000 live births),12 and Malawi (76 per 1000 live births).10
Mortality among HIV-1-infected infants was more than 5 times as high as uninfected infants
regardless of the timing of infection. By the end of the follow-up period, 42% of infected infants
had died, compared with 7.2% of uninfected HIV-exposed infants and 4.8% of HIV unexposed
infants. The mortality was the highest among infants infected early (at birth or 4–6 weeks) and
confirms other studies of perinatal transmission.14,15 The mortality rate among infants infected
early is more than 3-fold higher than the mortality rate of infants infected after 8 weeks. This
high mortality underscores the importance of early diagnosis and immediate referral to ART.
Increasing access to appropriate therapy is essential to prevent early mortality.16
Infant outcomes were strongly related to maternal outcomes. Infants in our study were
significantly more likely to die if their mother experienced an SAE or died, regardless of the
infant's HIV status. In univariate analysis, the mortality rate was more than 2-fold higher among
infants born to mothers who experienced an SAE and >4-fold higher among infants born to
mothers who died. Among the HIV-infected mothers, the relationship of the mother's health
to the outcome of the infant can also be quantified by the maternal CD4 count and the HIV
viral load at baseline. The lower the mother's CD4 count or the higher the viral load at
enrollment, the more likely the infant was to die in the first year. An infant of a mother with a
CD4 count <200 was 3 times more likely to die than a child of a mother with a CD4 count
>500. All the unadjusted maternal factors in the analysis of infant mortality continued to be
significant in the multivariate analysis including HIV infection, maternal morbidity and
mortality, CD4 count, and RNA viral load. Clinical diagnosis or WHO staging will not
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accurately identify all those with a low CD4 count. Therefore, CD4 count should be included
as part of routine prenatal HIV testing after post-test counseling of all infected women.
The limitations of this study include the underestimation of HIV-related morbidity and
mortality among infants. The HIV-status was not determined at death and some of these infants
may have been infected after their last negative test. Because of the testing sequence, an infant
with a negative HIV-test at birth and at 6–8 weeks who subsequently seroconverted and died
before the next follow-up visit would be classified as HIV-negative or unknown. Mothers or
infants receiving care elsewhere for an SAE were not captured by this analysis. Additionally,
data from 3 sites with diverse populations were pooled for this analysis and differences may
exist in standard of care, protocols for making clinical diagnoses, care-seeking behavior, and
access. However, these differences are not likely to be significant as our analysis demonstrated
similar outcomes in all 3 populations. Also, the exclusion criteria for this study selected for
asymptomatic women and excluded the symptomatic or chronically ill. This likely reduced the
maternal morbidity and mortality in this study population relative to a population-based
sample.
Because of the significant difference in mortality of infants born to HIV-infected compared
with uninfected mothers, the counseling message to all HIV-positive women should state this
increased risk of death to a newborn. This message will help women make informed
reproductive decisions. Additional programs should provide early and routine HIV testing for
all pregnant women, CD4 monitoring at the time of testing for infected mothers, early
diagnosis, and appropriate early treatment for HIV-exposed infants, a family support program
for infants of sick or deceased mothers, and appropriate and timely ART for infected mothers
and infants, including ART regimens for the PMTCT.
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TABLE 2
Causes of Infant Mortality, Overall and by Infant HIV-1 Infection Status
Cause of Mortality
HIV-1-Infected
Infants (N = 404)
Number of Deaths (%)
HIV-1-Uninfected
Infants (N = 1904)




Pneumonia 72 (17.8) 34 (1.8) 106 (4.4)
Diarrhea/gastroenteritis 26 (6.4) 16 (0.8) 42 (1.8)
Unknown cause 15 (3.7) 15 (0.8) 36 (1.5)
Sepsis 10 (2.5) 21 (1.1) 35 (1.5)
Malaria 10 (2.5) 15 (0.8) 25 (1.0)
Oral candidiasis 10 (2.5) 3 (0.2) 13 (0.5)
Tuberculosis 8 (2.2) 0 (0) 9 (0.4)
Other 49 (11.9) 53 (2.8) 142 (6.0)
Total causes 200 157 408
Total deaths 170† 130† 349†‡
*
Includes infants with no HIV test results.
†
Total causes of mortality is greater than the total number of deaths observed because some deaths were attributed to more than one etiology.
‡
Includes 49 deaths among infants with no HIV test results.
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